German Krankenkasse coverage for GLP-1 — Adipositas-Programm

This is incredibly helpful. I'm with AOK Niedersachsen and I've been trying to get Wegovy covered since mid-2025. My experience has been different — and worse.

AOK rejected my Antrag twice, citing that Wegovy is a "Lifestyle-Arzneimittel" and excluded under §34 SGB V (the section of German social law that excludes appetite suppressants from GKV coverage). They're treating it the same as old drugs like orlistat.

My Adipositas-Arzt (obesity specialist) filed a Widerspruch (formal objection) arguing that the G-BA (Gemeinsamer Bundesausschuss) ruling from September 2025 specifically states semaglutide 2.4mg is NOT classified as an Appetitzügler but as an Antiadipositum with metabolic effects. The Widerspruch is still pending after 8 weeks.

The German system is kafkaesque. One Krankenkasse approves it, the other rejects it for the same patient profile. It shouldn't depend on which insurance card you carry.

The §34 SGB V issue is THE central problem in Germany. Until the Bundestag amends the law to explicitly exclude modern GLP-1 agonists from the "Lifestyle" classification, individual Kassen will keep playing this game.

That said, there's been progress. The G-BA Beschluss (ruling) from 18. September 2025 did create a pathway. Key quote from the ruling:

"Semaglutid 2,4 mg (Wegovy) ist bei Patienten mit Adipositas Grad II oder höher (BMI ≥ 35 kg/m²) mit mindestens einer gewichtsbedingten Komorbidität verordnungsfähig, sofern ein strukturiertes multimodales Therapiekonzept vorliegt."

Translation: Wegovy IS prescribable for BMI 35+ with at least one weight-related comorbidity IF there's a structured multimodal therapy concept in place.

The problem is that this is a G-BA recommendation, not a binding directive. Each Krankenkasse decides independently whether to follow it.

Kassen known to cover Wegovy as of early 2026:

• Techniker Krankenkasse (TK) — yes, through besondere Versorgung
• BARMER — yes, case-by-case Einzelfallprüfung
• DAK-Gesundheit — yes, with Adipositas-Programm participation
• AOK Bayern — yes (but AOK Niedersachsen says no — go figure)

I went the Privatrezept (private prescription) route because my AOK Hessen also rejected coverage. Cost breakdown for Wegovy in Germany on private pay:

• 0.25mg starter: €141.18 (Apothekenverkaufspreis)
• 0.5mg: €141.18
• 1.0mg: €235.29
• 1.7mg: €235.29
• 2.4mg maintenance: €301.34/month

These are the official AVP prices — every Apotheke in Germany charges the same (Preisbindung). There is no shopping around on price.

At €301/month for the maintenance dose, it's not cheap but it's a fraction of US prices. I've been paying out of pocket since October 2025 and have lost 18kg. At some point the Kasse math will work out — treating my Adipositas-related conditions costs them far more than €301/month.

Dr.EndoEP — I'd strongly recommend escalating to the Sozialgericht (social court) if your Widerspruch is rejected. There have been several favorable rulings in 2025-2026 where courts ordered Kassen to cover Wegovy.

The key case is SG München, Urteil vom 14.11.2025, Az. S 7 KR 528/25 — the court ruled that TK was required to cover Wegovy for a patient with BMI 42 and T2D, finding that the §34 exclusion did NOT apply to semaglutide because its primary mechanism is metabolic, not appetite suppression.

Getting a Sozialgericht ruling takes 6-12 months, but it's free (no court costs in social court proceedings) and you can represent yourself without a lawyer.